Citi lowered the firm’s price target on Alpha Tau (DRTS) to $7 from $8 and keeps a Buy rating on the shares. The firm cites the pushed out timelines for Alpha DaRT’s commercialization in the U.S. for the target drop.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DRTS:
- Optimistic Growth Prospects and Strategic Developments Drive Buy Rating for Alpha Tau Medical Ltd
- Alpha Tau Treats First U.S. Patient with Alpha DaRT for Glioblastoma
- Alpha Tau announces first patient treated in study using Alpha DaRT tech
- Alpha Tau Medical to Present Pancreatic Cancer Research at 2026 ASCO Symposium
- Alpha Tau announces two Alpha DaRT abstracts at ASCO Symposium